| Revenue growth | FY26 revenue up 17% YoY to ₹14,278 Cr. |
|---|---|
| Margins | Adj. EBITDA margin at 27.1% for Q4FY26; 25.4% for FY26. |
| Demand visibility | High in chronic therapies like Cardiac (14.7%) and Anti-Diabetes (11.6%). |
| Management confidence | Strong confidence in domestic chronic and specialty growth pillars. |
Growth
FY26 revenue grew 17.0% YoY; EBITDA increased 15.5%. Q4FY26 revenue up 11.8% YoY.
Outlook
Targeting deeper CVM penetration (72% by FY26) and inorganic growth through super-specialty M&A.
Risks
International business faced headwinds from geo-political issues; anti-infectives segment saw muted growth.
Earnings Call filed with BSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,474.90
- Market cap
- ₹1,02,225 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.0×Sector 50.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma Investor Presentation: Key Takeaways
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma Q1 FY27 Results: Net Profit ₹574.1 Cr, Up 29.1% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,031 Cr (+12.9% YoY) and net profit of ₹574.1 Cr (+29.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹574.1 Cr · +29.1% YoY